Position of the Transparency Council – Xyrem (sodium oxybate)
At its meeting on14 April 2025, the Transparency Council adopted position No. 43/2025 on the validity of granting approvals for the reimbursement of the drug Xyrem (sodium oxybate) for the indication: narcolepsy with cataplexy